HIV-AIDS

Caring for older Americans’ teeth and gums is essential, but Medicare generally doesn’t cover that cost

Retrieved on: 
Friday, April 19, 2024

As dentistry scholars, we believe Koop also deserves credit for something else.

Key Points: 
  • As dentistry scholars, we believe Koop also deserves credit for something else.
  • Americans who rely on the traditional Medicare program for their health insurance get no help from that program with paying their dental bills aside from some narrow exceptions.
  • This group includes some 24 million people over 65 – about half of all the people who rely on Medicare for their health insurance.

‘Medically necessary’ exceptions

  • The list of circumstances that would lead patients to be eligible is short.
  • Some examples include patients scheduled for organ transplants or who have cancer treatment requiring radiation of their jaws.
  • But we believe that dental care is necessary for everyone, especially for older people.

Chew, speak, breathe

  • While many working Americans get limited dental coverage through their employers, those benefits are usually limited to as little as $1,000 per year.
  • And once they retire, Americans almost always lose even that basic coverage.
  • Rich Americans with Medicare coverage are almost three times more likely to receive dental care compared to those with low incomes.

Connected to many serious conditions

  • Having diabetes makes you three times as likely to develop gum disease because diabetes compromises the body’s response to inflammation and infection.
  • At the same time, treating diabetes patients for gum disease can help control their blood sugar levels.

Chemo can damage your teeth


Many cancer treatments can damage teeth, especially for older adults. As a result, Medicare has started to reimburse for dental bills tied to tooth decay or other oral conditions after they get chemotherapy or radiation treatment.

More than nice to have

  • Doctors and dentists are educated separately, and doctors learn very little about dental conditions and treatments when they’re in medical school.
  • Most dental electronic health records aren’t linked to medical systems, hindering comprehensive care and delivery of dental care to those in need.
  • Medical insurance was designed specifically to cover large, unpredictable expenses, while dental insurance was intended to mainly fund predictable and lower-cost preventive care.

Medicare Advantage plans

  • Until Medicare expands coverage to include preventive dental services for everyone, alternative plans such as Medicare Advantage, through which the federal government contracts with private insurers to provide Medicare benefits, serve as a stopgap.
  • In 2016, only 21% of beneficiaries in traditional Medicare had purchased a stand-alone dental plan, whereas roughly two-thirds of Medicare Advantage enrollees had at least some dental benefits through their coverage.


Frank Scannapieco is affiliated with The Task Force on Design and Analysis in Oral Health Research, and consults for the Colgate-Palmolive Company. Ira Lamster is a member of the Santa Fe Group. He currently receives consulting fees from Colgate, and research support from the CareQuest Institute.

Worldwide HIV/AIDS Diagnostics Industry to 2030 - Rapid Tests and ELISA Form the Major Markets for the HIV Diagnostic Tests - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023

With rising mortality, the government and non-government institutes are taking initiatives and providing funding for diagnostic treatment and prevention of HIV/AIDS.

Key Points: 
  • With rising mortality, the government and non-government institutes are taking initiatives and providing funding for diagnostic treatment and prevention of HIV/AIDS.
  • Technological advancement in screening tests, rising incidence of HIV and growing awareness about blood donation, act as the major drivers of the antibody testing market.
  • Rapid tests and ELISA form the major markets for the HIV diagnostic tests.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the HIV/AIDS Diagnostics market worldwide?

$8 Billion Worldwide Flow Cytometry Industry to 2027 - Featuring Agilent Technologies, Apogee Flow Systems, BD and Enzo Life Sciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023

Flow cytometry refers to a biophysical and laser-based analytical technology that is used in the analysis of the cells or micelles that are usually suspended in a fluid using a laser beam.

Key Points: 
  • Flow cytometry refers to a biophysical and laser-based analytical technology that is used in the analysis of the cells or micelles that are usually suspended in a fluid using a laser beam.
  • This technique aids in subclassifying cell types and detecting residual levels of disease through probes to develop the best treatment plan for the patient.
  • The increasing prevalence of chronic medical ailments, such as HIV-AIDS and cancer, is one of the key factors driving the growth of the market.
  • Furthermore, the widespread adoption of stem cell therapy is also enhancing the utilization of flow cytometry.

Lundquist Institute Investigator Dr. Eric Daar and Research Team Find That HIV Patients Benefit from Ingestible Sensor Technology on HIV Treatment

Retrieved on: 
Tuesday, November 15, 2022

The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.

Key Points: 
  • The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.
  • The team of researchers included investigators from UCLA, Nebraska Medical Center, Yale University, and Harvard University.
  • When ingested, it is sensed by a patchwith an embedded monitor and sensor that isworn by the patient.
  • Our study delivered especially promising results for those who have significant challenges in adhering to antiretroviral medications.

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors

Retrieved on: 
Thursday, October 6, 2022

DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.

Key Points: 
  • DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.
  • With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent.
  • "Susan is a highly respected and deeply experienced global executive in the healthcare industry, and we are pleased to welcome her to Mallinckrodt's Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors.
  • "I am excited to join the Mallinckrodt Board at this transformative moment for the Company," said Ms. Silbermann.

Global Vaccine Adjuvants Market Report (2022 to 2035) - by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022

The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and future potential of the vaccine adjuvant market.
  • According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
  • Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants.

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

Retrieved on: 
Friday, May 20, 2022

The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.

Key Points: 
  • The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.
  • "The ongoing complexities of the evolving pandemic require multiple lines of defense," said Dr Nigel Lindner, Chief innovation Officer.
  • The LumiraDx antigen test joins a select group of antigen tests the WHO has included in its Emergency Use Listing and represents the first microfluidic assay to meet the criteria.
  • LumiraDx has on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

Retrieved on: 
Friday, May 20, 2022

The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.

Key Points: 
  • The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.
  • "The ongoing complexities of the evolving pandemic require multiple lines of defense," said Dr Nigel Lindner, Chief innovation Officer.
  • The LumiraDx antigen test joins a select group of antigen tests the WHO has included in its Emergency Use Listing and represents the first microfluidic assay to meet the criteria.
  • LumiraDx has on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.

In Vitro Diagnostics (IVD) Quality Control Global Market Report 2022: Featuring Profiles of Bio-Rad Laboratories, Thermo Fisher Scientific, LGC, Abbott Laboratories and More - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 12, 2022

The "In Vitro Diagnostics (IVD) Quality Control Global Market Report 2022, By Product Type, Manufacturer Type, Application, End-Users" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Diagnostics (IVD) Quality Control Global Market Report 2022, By Product Type, Manufacturer Type, Application, End-Users" report has been added to ResearchAndMarkets.com's offering.
  • The in-vitro diagnostics (IVD) quality control market consists of sales of in-vitro diagnostics (IVD) quality control products by entities that are used to evaluate and validate the reliability of in-vitro diagnostics testing systems.
  • North America was the largest region in the in vitro diagnostics (IVD) quality control market in 2021.
  • It compares the in vitro diagnostics (IVD) quality control market with other segments of the in vitro diagnostics (IVD) quality control market by size and growth, historic and forecast.

Outlook on the Flow Cytometry Global Market to 2026 - by Product and Service, Technology, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 19, 2021

The increasing prevalence of chronic medical ailments, such as HIV-AIDS and cancer, is one of the key factors driving the growth of the market.

Key Points: 
  • The increasing prevalence of chronic medical ailments, such as HIV-AIDS and cancer, is one of the key factors driving the growth of the market.
  • How has the global flow cytometry market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global flow cytometry market?
  • What is the structure of the global flow cytometry market and who are the key players?